Detalhe da pesquisa
1.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Arthritis Rheum
; 64(4): 970-81, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22006202
2.
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Arthritis Rheum
; 64(3): 617-29, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21952978
3.
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
J Invest Dermatol
; 129(9): 2299-302, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19225543